API
< Back to all clusters
[HEALTH] · United States, Australia · 2 sources

started · updated

Botanix Pharmaceuticals reaffirms Sofdra safety profile in US journal

A peer-reviewed article published in The Journal of the American Academy of Dermatology (JAAD) has reaffirmed the safety and benefit-risk profile of Sofdra, a topical gel developed by Botanix Pharmaceuticals. The gel is FDA-approved for treating primary axillary hyperhidrosis, or excessive underarm sweating, in adults and children aged nine and older.

The report analyzed spontaneously reported adverse events in the United States from June 18, 2024, to January 31, 2026. During this period, 20,667 prescriptions were filled. Out of 194 reports involving 431 adverse events, 249 were identified as drug-related. The study concluded that no unexpected adverse events were observed, and the types of events were consistent with the known safety profile of sofpironium.

Serious drug-related adverse event reports accounted for 29 events, representing 0.08% of the postmarketing population. Botanix CEO Dr. Howie McKibbon noted that the transparent reporting of real-world safety data is important for both prescribers and patients.

Entities

Botanix Pharmaceuticals · FDA · Howie McKibbon · Sofdra · The Journal of the American Academy of Dermatology